GlassScriptPhysician profile
Mayra E Andrade
NPI 1124530357
$1,845.86
in general payments reported to CMS, 2019-2025
20 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $953 · 2023: $359 · 2024: $26.57 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $258.95 | 2023 | Aristada, Lybalvi, Aristada Initio |
| Amgen INC. | $217.13 | 2021-2022 | |
| Nevro Corp. | $158.56 | 2022 | |
| Novo Nordisk INC | $142.60 | 2021 | |
| Si-Bone, INC. | $130.73 | 2021 | |
| Neurocrine Biosciences, INC. | $130.44 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $126.60 | 2025 | Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $124.90 | 2022 | |
| Medtronic, INC. | $117.09 | 2022 | |
| Corcept Therapeutics | $111.58 | 2022 | |
| Acadia Pharmaceuticals INC | $96.57 | 2022 | |
| Amarin Pharma, INC. | $60.38 | 2021 | |
| Ironshore Pharmaceuticals INC. | $37.23 | 2023 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.48 | 2023 | Caplyta |
| Abbvie INC. | $26.57 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $19.00 | 2023 | Azstarys |
| Lilly USA, LLC | $16.97 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.14 | 2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.12 | 2021 | |
| Bioventus LLC | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayra Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.